Exagen Launches Test to Aid in the Detection of ANCA-Associated Vasculitis (AAV)
September 21 2020 - 8:25AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, today announced the launch of AVISE®
Vasculitis AAV, a new testing panel of individual analytes designed
to provide physicians with rapid and reliable results in the
assessment and monitoring of ANCA-associated vasculitis (AAV).
ANCA (anti-neutrophil cytoplasmic
antibody)-associated vasculitis is a group of autoimmune diseases
characterized by vascular inflammation and damage. Early signs and
symptoms vary greatly and are not always indicative of the severity
of the disease. Rapid and accurate testing is essential to prevent
death and long-term disability. AVISE® Vasculitis AAV is intended
for use in patients suspected of ANCA-associated vasculitis,
otherwise recognized as small vessel diseases: granulomatosis with
polyangiitis (GPA), microscopic polyangiitis (MPA), and
eosinophilic granulomatosis with polyangiitis (EGPA).
AVISE® Vasculitis AAV enhances Exagen’s catalogue
of AVISE® tests, allowing physicians further access to Exagen’s
specialty lab dedicated to autoimmune diseases.
“AVISE® Vasculitis AAV exemplifies the rigorous
quality that is at the core of all AVISE® testing products. As a
company dedicated to autoimmune diseases, this test is yet another
example of just how closely Exagen is listening to rheumatologists
while advancing our ‘own the hilltop’ strategy by providing
diagnostic, prognostic, and monitoring tests to address high unmet
needs,” said Ron Rocca, President and CEO of Exagen Inc.
About Exagen Inc.
Exagen is dedicated to transforming the care
continuum for patients suffering from debilitating and chronic
autoimmune diseases by enabling timely differential diagnosis and
optimizing therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand. Several of these products are based on our
proprietary Cell-Bound Complement Activation Products (CB-CAPs),
technology. CB-CAPs assess the activation of the complement system,
a biological pathway implicated in systemic lupus erythematosus
(SLE). Exagen’s goal is to enable rheumatologists to improve care
for patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis, or RA. Exagen’s model of
integrating testing products and therapeutics positions Exagen to
offer targeted solutions to rheumatologists and, ultimately, better
serve patients. For more information, please visit
www.Exagen.com.
Forward Looking Statements
Exagen cautions you that statements contained in
this press release regarding matters that are not historical facts
are forward-looking statements. These statements are based on the
company’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, express or implied
statements regarding the design and expected performance and
benefits of AVISE® Vasculitis AAV and its ability to provide
physicians with rapid and reliable results in the assessment and
monitoring of AAV. The inclusion of forward-looking statements
should not be regarded as a representation by Exagen that any of
its plans will be achieved. Actual results may differ from those
set forth in this press release due to the risks and uncertainties
inherent in Exagen’s business, including, without limitation: the
COVID-19 pandemic may continue to adversely affect our business,
financial condition and results of operations; the company’s
commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payers
and others in the medical community; third party payers not
providing coverage and adequate reimbursement for the company’s
testing products or promoted therapeutics; the company’s ability to
obtain and maintain intellectual property protection for its
testing products; regulatory developments affecting the company’s
business; and other risks described in the company’s prior press
releases and the company’s filings with the Securities and Exchange
Commission (SEC), including under the heading “Risk Factors” in the
company’s Annual Report on Form 10-K and any subsequent filings
with the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and Exagen undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
InvestorsWestwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com 646.677.1838
CompanyExagen Inc.Kamal Adawi,
Chief Financial Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024